Cagrilintide has similar GI tolerability, with one important difference: it causes more severe sickness at the start of treatment, which is thought to be because it strongly slows down stomach motility
The critical limitation for both compounds is the same: evidence is preclinical, human clinical data is either minimal (BPC-157) or nonexistent (KPV), and both are sourced through unregulated markets where product quality cannot be guaranteed
GHK-Cu products tend to be more expensive due to copper peptide sourcing and formulation complexity
They improve sleep quality, which is when most tissue repair occurs
Chemotherapy, one of the major treatment options for cancer, has limited efficacy in melanoma therapy largely due to the drug resistance followed by melanoma relapse after the initial response
In spite of promising preclinical and clinical outcomes, the best dosing, treatment duration, and combinatorial strategies for antioxidant treatments in ASD are poorly characterized